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in their article, Potenza et al. evaluated the influ-
ence of etanercept therapy on autonomic cardiovas-
cular regulation in young patients with moderate-to-
severe psoriasis without cardiovascular risk factors by 
measuring the time domain and frequency domain 
heart rate variability (hrV) parameters from 5-minute 
electrocardiogram (eCG) recordings (1). the authors 
used low frequency (LF), high frequency (hF) pow-
er, and LF/hF ratio as indices of frequency domain 
hrV and standard deviation of normal-to-normal 
intervals (SDNN); the mean root square of the sum 
of the squares of differences between consecutive 
r–r intervals (rMSSD) was used as the index of time 
domain hrV. the authors found that 12-week etan-
ercept therapy resulted in non-significant alterations 
in LF, hF, LF/hF ratio, SDNN, and rMSSD values. they 
concluded that treatment with etanercept in patients 
with moderate-to-severe psoriasis does not affect 
cardiovascular autonomic regulation and cardiovas-
cular risk.
hrV is a well-established, rapid, and noninvasive 
tool for the evaluation of the modulation of the car-
diac autonomic nervous system. hrV may also be a 
sensitive test for the detection of the cardiotoxicity 
of some chemotherapeutic agents (2). Methods for 
quantifying hrV are categorized as time domain and 
spectral or frequency domain. traditionally, spectral 
parameters such as LF, hF, and total power have been 
analyzed from standard 5-minute eCG segments, 
whereas most laboratories require at least 18 hours of 
valid data to measure time domain parameters such as 
SDNN and rMSSD in a 24-hour recording. in addition, 
the measurement of LF and hF power components 
is usually given in absolute values of power (millisec-
onds squared) or percentage. LF and hF can also be 
calculated in normalized units, which represent the 
relative value of each power component in propor-
tion to the total power. the representation of LF and 
hF in normalized units underlies the controlled and 
balanced behavior of the two branches of the auto-
nomic nervous system. Moreover, the normalization 
tends to minimize the effect of the changes in total 
power on the values of LF and hF components. thus, 
unnormalized units should be presented in conjunc-
tion with normalized versions of the same variables 
whenever possible in order to completely describe 
the distribution of power in spectral components (2). 
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